Aortyx has raised €2.4 million in its second investment round to develop its innovative minimally invasive aortic dissection patch, supported by key investors including NARA Capital.
Target Information
Aortyx is a spin-off from the Institut Químic de Sarrià and the Hospital Clínic de Barcelona, specializing in the development of innovative medical devices. The company has recently secured €2.4 million in its second investment round, facilitated through the investment platform Capital Cell. Noteworthy investors in this round include NARA Capital, Medex Partners, and loyal backers from the previous funding round.
The company is focused on creating a groundbreaking patch designed for the minimally invasive treatment of aortic dissections. Aortyx's primary objective is to reduce mortality rates associated with this critical condition while enhancing patients' quality of life.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Spain
Spain's healthcare sector is characterized by its emphasis on innovation and the adoption of advanced medical technologies. The country has a robust framework for biomedical research combined with a
Similar Deals
Asabys, Buenavista, GoHub Ventures, UI Investissement, Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind, individual investors → Quibim
2025
Asabys Partners and Buenavista Equity Partners → Quibim
2025
NARA Capital
invested in
Aortyx
in 2023
in a Series A deal
Disclosed details
Transaction Size: $2M